Scancell Holdings plc (LON:SCLP - Get Free Report)'s share price passed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of GBX 9.62 ($0.13) and traded as low as GBX 8.50 ($0.12). Scancell shares last traded at GBX 8.50 ($0.12), with a volume of 1,458,022 shares.
Scancell Price Performance
The stock has a market capitalization of £99.83 million, a price-to-earnings ratio of -462.50 and a beta of 0.35. The company has a quick ratio of 13.01, a current ratio of 3.42 and a debt-to-equity ratio of -566.79. The business's 50 day simple moving average is GBX 10.04 and its 200-day simple moving average is GBX 9.64.
Scancell (LON:SCLP - Get Free Report) last announced its quarterly earnings data on Thursday, September 11th. The company reported GBX (1.26) earnings per share (EPS) for the quarter. On average, research analysts forecast that Scancell Holdings plc will post -2.5361112 earnings per share for the current year.
Insider Buying and Selling at Scancell
In related news, insider Martin Diggle purchased 3,150,000 shares of Scancell stock in a transaction dated Friday, September 12th. The shares were bought at an average cost of GBX 9 per share, for a total transaction of £283,500. In the last 90 days, insiders have purchased 7,652,236 shares of company stock valued at $73,474,596. Company insiders own 15.15% of the company's stock.
About Scancell
(
Get Free Report)
Scancell LSE: SCLP is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers.
Scancell has developed a pipeline of ‘off-the-shelf' vaccines to induce immune responses and highly tumour specific monoclonal antibodies to redirect immune cells or drugs.
Read More
Before you consider Scancell, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Scancell wasn't on the list.
While Scancell currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
